Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2013 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Non-Current Deferred Tax Liability of $22000.0 for Q1 2026, down 91.94% year-over-year from $273000.0 in Q1 2025, and little changed quarter-over-quarter from $22000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non-Current Deferred Tax Liability history runs 14 years deep, the most recent figure standing at $22000.0 for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 91.94% year-over-year to $22000.0; the TTM figure through Mar 2026 stood at $22000.0 (down 91.94% YoY), while the FY2025 annual figure was $22000.0, down 91.94% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $22000.0, roughly flat from $22000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $2.1 million in Q1 2022, with the low at $22000.0 in Q4 2025.
- The 5-year median for Non-Current Deferred Tax Liability is $273000.0 (2023), against an average of $667705.9.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability jumped 132.21% in 2022, then tumbled 91.94% in 2025.
- Lineage Cell Therapeutics' Non-Current Deferred Tax Liability stood at $2.1 million in 2022, then sank by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then sank by 91.94% to $22000.0 in 2025, then changed by 0.0% to $22000.0 in 2026.
- Business Quant data shows LCTX's Non-Current Deferred Tax Liability at $22000.0 in Q1 2026, $22000.0 in Q4 2025, and $273000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22,000.00 |
| Jun 30, 2026 | 22,000.00 |
| Mar 31, 2026 | 22,000.00 |
| Mar 31, 2026 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 273,000.00 |
| Sep 30, 2025 | 273,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Mar 31, 2025 | 273,000.00 |
| Mar 31, 2025 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 273,000.00 |
| Mar 31, 2024 | 273,000.00 |